Kuros Biosciences Ag Stock Five Year Return
| CSBTF Stock | USD 21.40 3.90 15.42% |
Kuros Biosciences AG fundamentals help investors to digest information that contributes to Kuros Biosciences' financial success or failures. It also enables traders to predict the movement of Kuros Pink Sheet. The fundamental analysis module provides a way to measure Kuros Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kuros Biosciences pink sheet.
Kuros |
Kuros Biosciences AG Company Five Year Return Analysis
Kuros Biosciences' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
According to the company disclosure, Kuros Biosciences AG has a Five Year Return of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Kuros Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kuros Biosciences' direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kuros Biosciences could also be used in its relative valuation, which is a method of valuing Kuros Biosciences by comparing valuation metrics of similar companies.Kuros Biosciences is currently under evaluation in five year return category among its peers.
Kuros Fundamentals
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0667 | |||
| Profit Margin | (0.74) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 40.53 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 35.33 % | |||
| Shares Owned By Institutions | 16.83 % | |||
| Price To Earning | 0.33 X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.63 X | |||
| Revenue | 13.81 M | |||
| Gross Profit | 10.07 M | |||
| EBITDA | (5.29 M) | |||
| Net Income | (7.54 M) | |||
| Cash And Equivalents | 28.62 M | |||
| Cash Per Share | 0.87 X | |||
| Total Debt | 2.21 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 2.23 X | |||
| Cash Flow From Operations | (5.45 M) | |||
| Earnings Per Share | (0.24) X | |||
| Number Of Employees | 64 | |||
| Beta | 0.77 | |||
| Market Capitalization | 70.16 M | |||
| Total Asset | 91.34 M | |||
| Retained Earnings | (37 M) | |||
| Working Capital | 16 M | |||
| Current Asset | 18 M | |||
| Current Liabilities | 2 M | |||
| Z Score | 18.6 | |||
| Net Asset | 91.34 M |
About Kuros Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kuros Biosciences AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kuros Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kuros Biosciences AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Kuros Pink Sheet
Kuros Biosciences financial ratios help investors to determine whether Kuros Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kuros with respect to the benefits of owning Kuros Biosciences security.